Apricus Biosciences Inc (NASDAQ:APRI) Reaffirms Its Clinical & Regulatory Strategy For Symptomatic Secondary Hypogonadism Fispemifene

0
884

Apricus Biosciences Inc (NASDAQ:APRI), better known as a biopharmaceutical company developing innovative medicines in rheumatology and urology, reaffirmed its clinical and regulatory strategies. As per the reports, it would look forward to continuing same strategies to develop fispemifene as a response to the Complete Response Letter issued by FDA to Repros Therapeutics Inc.

Apricus has been working hard to develop fispemifene, which is a selective estrogen receptor modulator or SERM and can be used in the treatment of sexual dysfunction. It is quite common in men having symptomatic secondary hypogonadism.

Management Call

The senior management of the company is looking forward to implementing these strategies and witnessing desired results. According to Barbara Troupin, Chief Medical Officer, Apricus, the company has closely worked with Food and Drug Administration to develop a perfect clinical strategy for fispemifene.

The ongoing Phase 2b study has covered all the points suggested by FDA to ensure that everything remain in line with no confusion towards the end of the study. As a result of the continuous hard work and devotion shown by the production and R&D team, Apricus is well-positioned to bring first of its kind SERM product in the United States.

Troupin further added that the company expects to report the final results of the Phase 2b study sometime in the first quarter of 2016. If everything falls in line the way it’s expected, Apricus will continue to work along with FDA towards planning the registration trials of fispemifene during the next year.

The Phase 2b clinical trial is a randomized, parallel arm and multi-center study in about 160 hypogonadal men aged between 18-64 with sexual dysfunction related to low levels of testosterone or secondary hypogonadism.

Apricus Biosciences Inc (NASDAQ:APRI) looks forward to conducting further trials to make this product marketable as soon as possible. Details of these trials will be announced in the near future.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.